$Pacific Biosciences of California(PACB)$
In the past weeks, ARK Investment Management, led by Cathie Wood, acquired 1.09 million shares of Pacific Biosciences of California, reflecting renewed institutional interest in the genomics specialist.
This purchase by a prominent investor comes despite recent poor market sentiments after NVDA results and worrying AI bubble. There are financial challenges and signals industry confidence within biotechnology sectors
With ARK Investment Management’s substantial share acquisition amplifying attention on Pacific Biosciences
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
